Condition

EGFR T790M

ClinicalTrials.gov condition label

Clinical trials10

Recruiting1

Common interventions8

Lead sponsors shown8

Clinical trials

10 shown

Evaluation of Clinical Performance and IVD Test of LifeOS Digital PCR Liquid Biopsy Kits for EGFR T790M MutationNCT06573073 · 2024-09-06

Lazertinib 160mg in EGFR T790M NSCLCNCT05701384 · 2023-02-01

Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung CancerNCT05377788 · 2022-07-31

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCNCT04862780 · 2021-06-29

Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung CancerNCT04592666 · 2020-10-09

Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLCNCT05458726 · 2020-09-15

Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)NCT03532698 · 2020-08-01

Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)NCT03810066 · 2019-06-03

D-0316 in Patients With EGFR Positive Non Small Cell Lung CancerNCT03861156 · 2019-02-28

Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLCNCT03543683 · 2018-01-01

Common interventions

OsimertinibDRUG5 AspirinDRUG2 LazertinibDRUG2 AlmonertinibDRUG1 BLU-945DRUG1 CarboplatinDRUG1 D-0316DRUG1 PemetrexedDRUG1

Leading sponsors

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University2 Samsung Medical Center2 Blueprint Medicines Corporation1 Fudan University1 InventisBio Co., Ltd1 LifeOS Genomics Corporation1 Peking Union Medical College1 University Hospital, Essen1

Trial status mix

UNKNOWN5

COMPLETED3

RECRUITING1

TERMINATED1

Phase mix

PHASE26

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.